Penny Stocks For The Early-March Watch List
As March gets off to a great start, investors continue to look for penny stocks with the best chance of profitability. Given that most of the stock market is up on March 1st, it seems as though sentiment is reaching bullish levels once again. Whether this is a combination of a new vaccine arriving or just a fluke, it is undoubtedly good news. To secure the most profitability in one’s positions, the best idea is always to consider what is going on in the world. If we put aside the coronavirus for a second, we see that several other factors impact the trajectory of the stock market.
This includes the approval of the $1.9 trillion stimulus package and several good signs coming from the economy. This includes high job and manufacturing numbers as well as neutral bond movement. Obviously, everything is a bit tied to the Covid-19 pandemic as there is no way around this.
But, this novel circumstance presents investors with opportunities that could not be had otherwise. This includes finding penny stocks at low prices and capitalizing on future industry growth. With all of this in mind, here are four penny stocks that continue to show momentum in March. Will they be on your watch list this week?
Penny Stocks to Watch In March
- Assertio Holdings Inc. (NASDAQ: ASRT)
- SRAX Inc. (NASDAQ: SRAX)
- ENDRA Life Sciences Inc. (NASDAQ: NDRA)
- Timber Pharmaceuticals Inc. (NYSEA: TMBR)
Assertio Holdings Inc.
As a pharmaceutical company, Assertio Holdings has seen increased adoption due to the focus on biotech penny stocks. The company has a large pipeline of prescription compounds. This includes those that treat neurologic disorders, pain management, and inflammation needs. Ahead of the company’s planned Q4 2020 results which will come out on March 11th, let’s look at what Assertio has been up to.
Only a few weeks ago, Assertio announced a large registered direct offering. This offering, worth around $34.3 million in proceeds, should go toward corporate purposes and working capital. With the increased investments into biotech penny stocks, as mentioned above, companies are working out how to access this newfound capital. The most efficient way to do so is through capital-raising endeavors like this.
A few months ago, Assertio announced some large changes to its business due to the Covid pandemic. Chairman Arthur Higgins stated that “to adapt to the current market environment and maximize shareholder value, we are refocusing and substantially reducing our operating footprint, which is expected to result in significant cost savings. Given recent changes in our product payor mix as well as the continued near-term impact from the Covid-19 pandemic, we believe that restructuring the business will allow us to continue to provide our differentiated products to patients and better position Assertio for future success.”
Later this month the company participates at the Roth Conference. For those following ASRT right now, keep March 15th on your calendar as the date for this event.
While SRAX stock may be unfamiliar to many, the company has been making big waves in the tech industry. SRAX provides marketing and advertising tools. These tools are used in combination with machine learning and AI to provide management, marketing services and media tracking across its platforms. The company works primarily in the fintech space, where it has a large range of products. This includes its LD Micro Index, which screens micro-cap companies automatically to be included within it.
Over the past few years, the LD Micro Index has bounced up tremendously. Only a few weeks ago, President of the LD Index, Chris Lahiji stated that “I cannot believe what I’ve seen in the past year. The LD Micro Index has more than tripled from its March 2020 lows. The tiniest public companies were also some of the biggest winners last year, and already year-to-date. As each day goes by, the index becomes more and more consequential to the next generation of great companies.”
In addition to this, the company offers its SaaS platform known as Sequire. Recently, the company announced that Sequire has more than 3 million retail investors within it. This platform works by identifying potential retail investors to build a community for investing. Something else that has captured investors’ interest is the relationship that SRAX could have to the cryptocurrency & blockchain industry.
The company’s subsidiary is BIGtoken. It’s a consumer data management and distribution system. BIG offers consumers choice, transparency, and compensation for their data, essentially allowing them to opt-in to receiving ads and get paid for them. The system also provides advertisers, and media companies access to transparent, verified consumer data to better reach and serve audiences. With the recent focus back on Bitcoin, many companies with some exposure to this market segment have gained momentum.
ENDRA Life Sciences Inc.
While ENDRA Life Sciences is a biotech company, it works primarily in the medical devices sector. The company produces Thermo Acoustic Enhanced UltraSound (TAEUS) based products, a novel imaging system. This system is comparable to a CT or MRI but is more than 50x cheaper. Also, those who want to use it do not need to buy an entirely new machine. Rather, the company states that it is compatible with more than 1 million ultrasound systems used globally. The initial goal of this product is to measure the amount of fat in the liver. Because chronic liver conditions affect more than 1 billion people worldwide, the demand for new imaging and measurement devices remains high.
Last month, the company announced a partnership with Inselspital University in Bern, Switzerland. This clinical study partnership should help to identify just how well this product works. The Chief Commercial Officer at ENDRA, Renaud Maloberti, stated that “we are very excited that Inselspital Bern, a renowned Swiss clinical and teaching institution, is evaluating TAEUS as a non-invasive tool to characterize NAFLD, a condition that impacts more than 1 billion people globally.”
Research partnerships like these are crucial to success in the biotech industry. This is because they allow for faster development and many scientists to get their hands on a given product. Based on these recent developments, NDRA could be one of the penny stocks to watch.
Timber Pharmaceuticals Inc.
While no news sparked TMBRs 27% rally on March 1st, the pharmaceutical company does have a lot to back this up. As a specialty biopharmaceutical company, Timber develops treatments for both rare and orphan disorders. It has a large range of investigational drugs in its pipeline. These drugs utilize existing CMC (chemistry, manufacturing, and control) to be as effective as possible. Currently, the company is intent on creating treatments for dermatologic diseases. This includes congenital ichthyosis, facial angiofibromas, and more. Around a month or so ago, the company received Orphan Drug Designation from the FDA for its TMB-003 substance. This compound is aimed at treating systemic sclerosis in a broad group of patients.
John Koconis, CEO of Timber, stated that “people who are living with systemic sclerosis or scleroderma often struggle with their quality of life because the condition can be disfiguring and may cover joints and cause pain that affects movement and mobility. Currently, there is no FDA-approved treatment for any cutaneous symptoms in scleroderma. We are pleased to receive orphan drug designation for our investigational treatment and look forward to advancing into clinical-stage research.”
Orphan drug designation is not easy to receive in any way. And with this, the company should be able to move further to produce a commercially available substance for this application. While it will likely take some time, there are more than 200,000 people in the U.S. alone that could benefit.